期刊文献+

EGFR酪氨酸激酶抑制剂HS-10296诱导三阴乳腺癌MDA-MB-231细胞发生自噬和凋亡 被引量:13

EGFR tyrosine kinase inhibitor HS-10296 induces autophagy and apoptosis in triplenegative breast cancer MDA-MB-231 cells
下载PDF
导出
摘要 目的探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKT)HS-10296对三阴乳腺癌MDA-MB-231细胞的增殖抑制作用及潜在分子机制。方法HS-10296处理MDA-MB-231细胞24、48、72 h。CCK-8法检测MDA-MB-231细胞存活率;集落克隆法检测HS-10296对细胞的增殖抑制作用;JC-1与流式细胞术检测细胞凋亡情况;电镜观察细胞超微结构;自噬抑制剂氯喹预处理后分为不含药物的对照组、单用氯喹组、单用HS-10296(4、6μmol/L)组和两者联合组,CCK-8法检测MDA-MB-231细胞对HS-10296的敏感性变化;Western blot分析HS-10296对MDA-MB-231细胞凋亡和自噬相关蛋白以及EGFR信号通路的影响。结果CCK-8和集落克隆结果显示,HS-10296对三阴乳腺癌MDA-MB-231细胞具有增殖抑制作用(P<0.01),24、48、72 h的IC50值分别为8.393、2.777、2.016μmol/L。JC-1与流式细胞术显示HS-10296可诱导细胞发生凋亡,8μmol/L HS-10296处理后,细胞凋亡率为(21.63±2.97)%。电镜观察到经HS-10296处理后,细胞内出现自噬囊泡,使用氯喹预处理细胞后,观察到抑制自噬可增强HS-10296诱导的细胞死亡。Western blot显示经HS-10296处理后凋亡相关蛋白Caspase-3出现活化形式,并对其底物PARP进行剪切。自噬相关蛋白轻链3B表达高于对照组(P<0.01),同时,HS-10296可抑制细胞内EGFR及AKT蛋白的磷酸化。结论HS-10296可通过抑制EGFR/PI3K/AKT信号通路,抑制MDA-MB-231细胞增殖,诱导细胞发生自噬和凋亡。 Objective To investigate the inhibitory effect of epidermal growth factor receptor tyrosine kinase inhibitor(EGFRTKI)HS-10296 on the proliferation of triple-negative breast cancer(TNBC)MDA-MB-231 cells and explore the possible molecular mechanism.Methods MDA-MB-231 cells were treated with HS-10296 for 24,48,or 72 h,and CCK-8 assay was used to assess the changes in the cell viability.The inhibitory effect of HS-10296 on cell proliferation was determined by clonogenic assay.JC-1 and flow cytometry were employed for analyzing the cell apoptosis,and the ultrastructure of the cells was observed under electron microscope.After pretreatment with autophagy inhibitor chloroquine(CQ),MDA-MB-231 cells were divided into control group,CQ treatment group,HS-10296(4 and 6μmol/L)treatment groups and combined treatment groups,and the sensitivity of the treated cells to HS-10296 was determined using CCK-8 assay.The effects of HS-10296 on EGFR pathway and apoptosis-and autophagy-related proteins in MDA-MB-231 cells were investigated using Western blotting.Results HS-10296 significantly inhibited the proliferation of MDA-MB-231 cells with IC50 values at 24,48 and 72 h of 8.393,2.777 and 2.016μmol/L,respectively.JC-1 and flow cytometry showed that HS-10296 induced obvious apoptosis of MDA-MB-231 cells,which showed an apoptosis rate of(21.63±2.97)% following treatment with 8μmol/L HS-10296.Autophagy vesicles were observed in the cells treated with HS-10296 under electron microscope.In MDA-MB-231 cells pretreated with CQ,inhibition of autophagy significantly enhanced HS-10296-induced cell death.Western blotting showed that the apoptosis-related protein caspase-3 was activated after HS-10296 treatment to cut its substrate PARP.The expression of autophagy-related protein light chain 3B(LC3B)was significantly enhanced after HS-10296 treatment(P<0.01),which also resulted in inhibited phosphorylation of EGFR and AKT proteins in the cells.Conclusion HS-10296 can inhibit the proliferation and induce autophagy and apoptosis of MDA-MB-231 cells by inhibiting the EGFR/PI3K/AKT signaling pathway.
作者 葛贤明 周巧 张语涵 周文静 伍宇 甄诚 张梦晓 范方田 陈刚胜 赵军军 刘浩 GE Xianming;ZHOU Qiao;ZHANG Yuhan;ZHOU Wenjing;WU Yu;ZHEN Cheng;ZHANG Mengxiao;FAN Fangtian;CHENGangsheng;ZHAO Junjun;LIU Hao(School of Pharmacy,Bengbu Medical College//Anhui Provincial Engineering Technology Research Center of Biochemical Pharmaceuticals,Bengbu 233030,China)
出处 《南方医科大学学报》 CAS CSCD 北大核心 2020年第7期981-987,共7页 Journal of Southern Medical University
基金 安徽省科技重大专项(201903a07020029) 国家“重大新药创制”科技重大专项(2019ZX09303001) 安徽省创新创业领军人才特殊支持计划项目(2016) 安徽省教育厅重点项目(KJ2018A0238) 研究生科研创新计划项目(Byycxz1904) 国家级大学生创新创业项目(201710367006)。
关键词 三阴乳腺癌 表皮生长因子受体 自噬 凋亡 triple-negative breast cancer epidermal growth factor receptor autophagy apoptosis
  • 相关文献

参考文献3

二级参考文献206

  • 1Yao Long, Xiao-Tian Lin, Kun-Lun Zeng and Lian Zhang Zhanjiang, China Department of Infectious Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China ,Haibin Centre Hospital, Zhanjiang 524005, China ,Centre of Hepatology of Nanfang Hospital, First Military Medical University, Guang- zhou 510515, China.Efficacy of intramuscular matrine in the treatment of chronic hepatitis B[J].Hepatobiliary & Pancreatic Diseases International,2004,3(1):69-72. 被引量:21
  • 2Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 2006, 12(24): 7232-7241.
  • 3Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007- 7(3): 169-181.
  • 4Pao W, Miller VA. Epidermal growth factor receptor mutations, small- molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.J Clin Oncol, 2005, 23(11): 2556-2568.
  • 5Schleger C, Heck R, Steinberg P. The role of wild-type and mutated N-ras in the malignant transformation of liver cells. Mol Carcinog, 2000j 28(1): 31-41.
  • 6Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncolj 2005, 23(25): 5900-5909.
  • 7Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005, 2(1): el7.
  • 8Pratilas CA- Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res, 2008, 68(22): 9375-9383.
  • 9Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curt Opin Pharmacol, 2008, 8 (4): 413-418.
  • 10Zhu CQ.- Santos GD, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol, 2008, 26(26): 4268-4275.

共引文献153

同被引文献87

引证文献13

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部